• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Green tea compound may improve cancer drugs
Conclusion This study developed a new way of packaging and carrying protein drugs by combining them with a green tea extract called Epigallocatechin-3-O-gallate (EGCG), which itself may have anti-cancer properties. They formed a complex between derivatives of EGCG and the protein cancer drug Herceptin. Tests in the laboratory and in mice indicated it might have better anti-cancer properties than non-complexed free Herceptin. This is encouraging research and may lead to improvements in delivery mechanisms for protein drugs further down the line. But this research remains at a very early stage of development. The results f...
Source: NHS News Feed - October 6, 2014 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Precision medicine is coming, but not anytime soon
President Obama’s announcement of a Precision Medicine Initiative was one of the few items in this year’s State of the Union address to garner bipartisan support. And for good reason. Precision medicine, also known as personalized medicine, offers the promise of health care — from prevention to diagnosis to treatment — based on your unique DNA profile. Who wouldn’t want that? We’ve already had a taste of precision medicine. Relatively low-tech therapies like eyeglasses, orthotic devices, allergy treatments, and blood transfusions have long been personalized for the individual. Genetic analysis o...
Source: New Harvard Health Information - March 26, 2015 Category: Consumer Health News Authors: Beverly Merz Tags: Health care personalized health care precision medicine Source Type: news

Subclinical Myocardial Impairment Occurred in Septal and Anterior LV Wall Segments After Anthracycline-Embedded Chemotherapy and did not Worsen During Adjuvant Trastuzumab Treatment in Breast Cancer Patients.
Abstract In a previous study of breast cancer patients, we found changes in cardiac function and size during the early stages of adjuvant trastuzumab (Herceptin(®)) therapy. Here we present a subgroup analysis of this patient cohort. This subgroup received a anthracycline-embedded chemotherapy followed by at least 3 months up to 6 months of adjuvant Herceptin(®) therapy. Twenty-seven female breast cancer patients with Her-2/-neu overexpression were studied using conventional echocardiography and 2D speckle tracking. These methods were done before anthracycline-embedded chemotherapy, before adjuvant trastuzumab...
Source: Cardiovascular Toxicology - May 29, 2015 Category: Cardiology Authors: Lange SA, Jung J, Jaeck A, Hitschold T, Ebner B Tags: Cardiovasc Toxicol Source Type: research

A moment that changed me: the chance to use new life-saving cancer drugs
A stroke of luck at a bleak time meant I got to take the ground-breaking Herceptin. It allowed me to live, and follow my dream of becoming an authorThough I loved being an English teacher, my dream from childhood was to be a writer. Aged 34, I was head of English in a secondary school, newly married, and about to start a family. Just three weeks after the wedding I found something strange in my right breast. It was more of a mass than a lump.On the 11 November 2004 at 1.35pm, I was told I had cancer. The words I remember were “no cure”, “mastectomy”, and “breast cancer and pregnancy don’t mix” – all said in...
Source: Guardian Unlimited Science - June 2, 2016 Category: Science Authors: Emma Carroll Tags: Breast cancer Health Medical research Books Source Type: news

Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study
Abstract We critically examined long-term cardiovascular (CV) outcomes and overall survival (OS) of breast cancer (BC) patients who had cardiotoxicity during adjuvant trastuzumab treatment requiring discontinuation in a population-based sample. This was a retrospective cohort of early-stage BC patients diagnosed before 2010 and treated with trastuzumab in Ontario. Patients were stratified based on trastuzumab doses received: 1–8, 9–15, ≥16 (therapy completion). Time-dependent multivariable Cox models were used to analyze primary endpoint OS, and the following composite endpoints: hospitalization/emergency ro...
Source: Breast Cancer Research and Treatment - June 5, 2016 Category: Cancer & Oncology Source Type: research

Targeted Cancer Therapies.
Abstract Targeted cancer therapies involve chemotherapeutic agents that attack, directly or indirectly, a specific genetic biomarker found in a given cancer. Targeted oncology includes monoclonal antibodies, small molecule inhibitors, antibody-drug conjugates, and immunotherapy. For example, the monoclonal antibodies trastuzumab and pertuzumab target human epidermal growth factor receptor 2 (HER2) and are used when treating HER2-positive breast cancer. Although targeted oncology has improved survival by years for some incurable cancers such as metastatic breast and lung cancer, as few as 8% of patients with advanc...
Source: American Family Physician - January 30, 2021 Category: Primary Care Authors: Smith CEP, Prasad V Tags: Am Fam Physician Source Type: research

Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study
CONCLUSION: Women with BC had increased incidence of CVD events, CVD-related mortality, and all-cause mortality compared with women without BC, and risks varied according to the history of cancer treatment received. Studies are needed to determine how women who received BC treatment should be cared for to improve cardiovascular outcomes.PMID:35385342 | DOI:10.1200/JCO.21.01736
Source: Clinical Breast Cancer - April 6, 2022 Category: Cancer & Oncology Authors: Heather Greenlee Carlos Iribarren Jamal S Rana Richard Cheng Mai Nguyen-Huynh Eileen Rillamas-Sun Zaixing Shi Cecile A Laurent Valerie S Lee Janise M Roh Margarita Santiago-Torres Hanjie Shen Dawn L Hershman Lawrence H Kushi Romain Neugebauer Marilyn L Kw Source Type: research